2 research outputs found
Consensus paper from thoracic oncology experts about the definition of synchronous oligometastatic non-small cell lung cancer
No full textIntroduction: Improved outcome has been shown in patients with synchronous oligometastatic non-small cell lung cancer (sOM-NSCLC) when treated with radical intent. As a uniform definition of sOM-NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process. Methods: A pan-European multidisciplinary consensus group was established. Consensus questions were built based on current controversies, and definitions extracted from a survey, cases and a systematic review. This statement was formulated during a consensus meeting. Results: Defining sOM-NSCLC Definition of sOM-NSCLC is relevant when a radical treatment is technically feasible for all tumor sites with acceptable toxicity, that may modify the disease course leading to long term disease control. Based on the review, a maximum of 5 metastasesand 3 organs is proposed. Mediastinal lymph node involvement is not counted as a metastatic site. Staging of sOM-NSCLC A 18fluorodeoxyglucose-positron emission tomography (18F-FDG-PET-CT) and brain imaging were considered mandatory. A dedicated liver MRI is advised for a solitary liver metastasis, and thoracoscopy and biopsies of distant ipsilateral pleural sites for a solitary pleural metastasis. For mediastinal staging, a 18FDG-PET-CT is the minimum requirement, with pathological confirmation recommended if this influences the treatment strategy. Biopsy of a solitary metastatic location is mandated unless the multidisciplinary team is of the opinion that the risks outweigh the benefits. Conclusion: A multidisciplinary consensus statement on the definition and staging of sOM-NSCLC has been formulated. This statement will help to standardise inclusion criteria in future clinical trials
Consensus paper from thoracic oncology experts about the definition of synchronous oligometastatic non-small cell lung cancer
No full textIntroduction: Improved outcome has been shown in patients with synchronous oligometastatic non-small cell lung cancer (sOM-NSCLC) when treated with radical intent. As a uniform definition of sOM-NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process. Methods: A pan-European multidisciplinary consensus group was established. Consensus questions were built based on current controversies, and definitions extracted from a survey, cases and a systematic review. This statement was formulated during a consensus meeting. Results: Defining sOM-NSCLC Definition of sOM-NSCLC is relevant when a radical treatment is technically feasible for all tumor sites with acceptable toxicity, that may modify the disease course leading to long term disease control. Based on the review, a maximum of 5 metastasesand 3 organs is proposed. Mediastinal lymph node involvement is not counted as a metastatic site. Staging of sOM-NSCLC A 18fluorodeoxyglucose-positron emission tomography (18F-FDG-PET-CT) and brain imaging were considered mandatory. A dedicated liver MRI is advised for a solitary liver metastasis, and thoracoscopy and biopsies of distant ipsilateral pleural sites for a solitary pleural metastasis. For mediastinal staging, a 18FDG-PET-CT is the minimum requirement, with pathological confirmation recommended if this influences the treatment strategy. Biopsy of a solitary metastatic location is mandated unless the multidisciplinary team is of the opinion that the risks outweigh the benefits. Conclusion: A multidisciplinary consensus statement on the definition and staging of sOM-NSCLC has been formulated. This statement will help to standardise inclusion criteria in future clinical trials
